MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 05-14-2026
AstraZeneca PLC Total Non Current Liabilities 2011-2026 | AZN
Annual Total Non Current Liabilities AstraZeneca PLC
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34.7 B | 35.3 B | 31.4 B | 33.1 B | - | 30.8 B | 28.7 B | 30.3 B | 30.3 B | 30.6 B | 26.7 B | 21.6 B | 16.6 B | 15.7 B | 13.6 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 35.3 B | 13.6 B | 27.1 B |
Quarterly Total Non Current Liabilities AstraZeneca PLC
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34.7 B | 34.1 B | 35.3 B | 36.2 B | 31.4 B | 32.8 B | - | - | - | - | 43.5 B | - | 35.7 B | - | 30.8 B | - | 28.1 B | - | 28.7 B | - | 30.8 B | - | 30.3 B | - | 29.9 B | - | 30.3 B | - | 34 B | - | 30.6 B | - | - | - | 26.7 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 43.5 B | 26.7 B | 32.4 B |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
79.1 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
158 K | - | 1.35 % | $ 17.8 M |  China |
 |
Amphastar Pharmaceuticals
AMPH
|
69.4 M | $ 16.81 | -2.83 % | $ 786 M |  USA |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
30.4 M | $ 7.58 | -3.19 % | $ 208 M |  Israel |
 |
Athira Pharma
ATHA
|
876 K | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
7.32 M | - | 0.74 % | $ 768 M | Israel |
 |
Galera Therapeutics
GRTX
|
64 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
645 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
AbCellera Biologics
ABCL
|
326 M | $ 4.08 | -7.39 % | $ 1.22 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.61 | 1.26 % | $ 428 M | Britain |
 |
Compugen Ltd.
CGEN
|
31.3 M | $ 2.77 | -8.75 % | $ 259 M | Israel |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
BioNTech SE
BNTX
|
622 M | $ 89.59 | -2.61 % | $ 21.7 B | Germany |
 |
Coherus BioSciences
CHRS
|
189 M | $ 1.6 | -2.15 % | $ 187 M | USA |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.19 M | $ 3.43 | -3.65 % | $ 5.65 M | Israel |
 |
Aeterna Zentaris
AEZS
|
14 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
383 M | $ 0.72 | -2.32 % | $ 32.9 M | Israel |
 |
Esperion Therapeutics
ESPR
|
355 M | $ 3.13 | 0.16 % | $ 651 M | USA |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
Eton Pharmaceuticals
ETON
|
4.56 M | $ 30.12 | -1.94 % | $ 810 M | USA |
 |
Aptose Biosciences
APTO
|
27.9 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | USA |
 |
Exelixis
EXEL
|
63.6 M | $ 50.55 | -1.08 % | $ 13.7 B | USA |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
8.11 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
167 M | $ 21.54 | -0.16 % | $ 2.74 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
10.2 M | - | 3.16 % | $ 1.9 M | USA |
 |
Fortress Biotech
FBIO
|
83.9 M | $ 2.39 | 3.91 % | $ 66.7 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | USA |
|
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
15.9 M | - | - | $ 2.17 B | USA |
|
Forte Biosciences
FBRX
|
10.5 M | $ 23.52 | -1.86 % | $ 305 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
24.6 M | $ 10.11 | 9.36 % | $ 289 M | USA |
 |
Aileron Therapeutics
ALRN
|
4.59 M | - | 10.36 % | $ 9.8 M | USA |